InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Stock Information for InMed Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date
InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents
InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease
InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.